SPP1 and neoplasm: On the contrary, M2-type TAMs suppress T cell-mediated anti-tumor immunity through multiple signaling pathways, including the CD86/cytotoxic T-lymphocyte associated protein 4 (CTLA4) and secreted phosphoprotein 1 (SPP1)/CD44 pathways.